CYTOTECT CP

This brand name is authorized in Austria, Croatia, Estonia, Romania, UK.

Active ingredients

The drug CYTOTECT CP contains one active pharmaceutical ingredient (API):

1	Cytomegalovirus immunoglobulin UNII 129L90A25N - HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN
	Cytomegalovirus immunoglobulin is used as a CMV-specific polyclonal immunoglobulin preparation that binds to CMV surface antigens thereby neutralizing the potential of CMV from entering host cells and presenting the CMV particle for phagocytosis. Furthermore, cytomegalovirus immunoglobulin can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses.
	Read more about Cytomegalovirus immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CYTOTECT CP BIOTEST Solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BB09	Cytomegalovirus immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1669158, 1669169
GB	Medicines & Healthcare Products Regulatory Agency	380808, 380814
HR	Agencija za lijekove i medicinske proizvode	HR-H-379332860
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69368001, W69368002